Title: USE OF K237 AS THERAPEUTIC AGENT

Abstract: The present invention is directed to the use of the peptide compound His-Thr-Met-Tyr- Tyr-His-His-Tyr-Gln-His-His-Leu-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide His-Thr-Met-Tyr-Tyr-His-His-Tyr-Gln-His-His-Leu-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

<table>
<thead>
<tr>
<th>INV.</th>
<th>A61K38/10</th>
<th>A61P3/00</th>
<th>A61P9/00</th>
<th>A61P11/00</th>
<th>A61P25/28</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A61K31/00</td>
<td>A61P35/00</td>
<td>A61P37/00</td>
<td>A61P31/18</td>
<td></td>
</tr>
</tbody>
</table>

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, COMPENDEX, WPI Data, EMBASE, BIOSIS, CHEMABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>HETIAN L ET AL: &quot;A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor&quot; JOURNAL OF BIOLOGICAL CHEMISTRY 20021108 AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY INC. US, vol. 277, no. 45, 8 November 2002 (2002-11-08), pages 43137-43142, XP002533567 abstract</td>
<td></td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

"X" document considered to be of particular relevance

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claims(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"Y" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"V" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"*" document of the same patent family

**Data of the actual completion of the international search**

7 July 2009

**Date of mailing of the international search report**

03/09/2009

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 940-2040, Fax (+31-70) 940-2016

Authorized officer

Vandenbogaerde, Ann
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>DE SOULTRAIT V RICHARD ET AL: &quot;Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase&quot; CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 10, no. 10, 1 September 2003 (2003-09-01), pages 1765-1778, XP009100848 ISSN: 0929-8673 the whole document</td>
<td>1-12</td>
</tr>
</tbody>
</table>